Anti-Infectives and the Lung

Stefano Aliberti is Associate Professor in Respiratory Medicine at the University of Milan and consultant at the Policlinico Hospital in Milan (Italy). He co-founded the European Bronchiectasis Registry (EMBARC), and is the Director of the Italian Bronchiectasis Registry and the Italian Registry of Pulmonary Non-tuberculous Mycobacteria. James D. Chalmers is Clinical Senior Lecturer and Honorary Consultant at the University of Dundee (UK). He runs a translational research group primarily focused on developing novel diagnostics and treatments for respiratory infections, with current major programmes looking at neutrophilic inflammation and the microbiome in bronchiectasis, COPD and severe asthma. He is the co-founder and Chair of EMBARC. Mathias W. Pletz, Professor for Infectious Diseases, is a board-certified physician for internal medicine, pulmonology and infectious diseases, and the Head of the Centre for Infectious Diseases and Infection Control of the University Hospital in Jena (Germany). He also leads a clinical research group focusing on novel diagnostic and therapeutic strategies against MDR bacterial pathogens, funded by the German Ministry for Science and Education. Mathias Pletz is the Deputy Director of the German Competence Network for Community-Acquired Pneumonia (CAPNETZ), a member of the Board of Directors of the German Society for Infectious Diseases (DGI) and scientific advisor for the German Robert Koch Institute.

Antibiotics for pulmonary infections: an overview; Antibiotic resistance in pulmonary infections: mechanisms and epidemiology; Antibiotics in critical care: dosing, therapeutic drug monitoring and continuous infusions; Inhaled antibiotics in chronic airway infections; Inhaled antibiotics in critical care; Identifying patients with pneumonia due to MDR organisms coming from the community; Antibiotic stewardship in the community; Antibiotic stewardship in the hospital setting; Antibiotics in acute exacerbation of asthma and COPD; Antifungals in pulmonary infections: to whom, when and how?; Long-term oral antibiotic treatment: why, what, when and to whom?; Macrolide therapy for patients with pneumonia: a triple-edged sword; Treatment options for MDR-and XDR-TB; Perspectives on antibiotic treatment of NTM pulmonary disease; Antibiotics for pleural infections; Antibiotics in interstitial lung diseases; Insights into antibiotic use in children with CAP; New antibiotic development for pulmonary infections: New Drugs for Bad Bugs and beyond; Combination antibiotic therapy and synergy in HAP and VAP